Ardelyx gains on report Zydus Lifesciences in talks to purchase

Ardelyx gains on report Zydus Lifesciences in talks to purchase
Ardelyx wins long battle for FDA approval of kidney-disease treatment
#earnings after the close https://t.co/lObOE0dgsr $QCOM $MELI $ETSY $ALB $SEDG $FSLY $RUN $MRO $APA $HUBS $TRIP $ZG $ARDX $MOS $O $LMND $PSA $UPWK $CFLT $ACLS $REI $QRVO $ALL $MET $VET $ESTE $VAC $YELL $EQIX $SITM $ASPN $HDSN $WMB $DHT $RELY $MKSI $CPE $JOBY $XPO $IR $UDMY… https://t.co/fhIjlzIUMC
782.31MUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US0396971071
CUSIP
039697107
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-0.08
Book Value
0.60
Dividend Share
-
Dividend Yield
-
Earnings Share
-0.23
Wall Street Target Price
12.80
EPS Estimate Current Year
-0.19
EPS Estimate Next Year
0.29
EPS Estimate Current Quarter
-0.0496
EPS Estimate Next Quarter
0.043
Most Recent Quarter
-
Revenue TTM
450,894,016
Gross Profit TTM
338,279,008
EBITDA
-32,106,000
Profit Margin
-12.35%
Return On Assets TTM
-4.25%
Return On Equity TTM
-38.61%
Revenue Per Share TTM
1.841
Qtly Revenue Growth YOY
23.80%
Diluted Eps TTM
-0.23
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
8
Price Sales TTM
1.735
Price Book MRQ
5.2499
Enterprise Value Revenue
1
Enterprise Value EBITDA
130
903.08
3.20%227.40
2.97%965.00
0.55%314.92
0.35%900.30
0.00%139.16
0.00%528.21
-4.77%355.10
-2.26%34.64
-2.01%153.70
-1.47%